Details for New Drug Application (NDA): 209446
✉ Email this page to a colleague
NDA 209446 describes MIRABEGRON, which is a drug marketed by Alkem Labs Ltd, Lupin Ltd, Sawai Usa, and Zydus Pharms, and is included in four NDAs. It is available from three suppliers. Additional details are available on the MIRABEGRON profile page.
The generic ingredient in MIRABEGRON is mirabegron. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the mirabegron profile page.
The generic ingredient in MIRABEGRON is mirabegron. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the mirabegron profile page.
Summary for 209446
| Tradename: | MIRABEGRON |
| Applicant: | Sawai Usa |
| Ingredient: | mirabegron |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 25MG | ||||
| Approval Date: | Dec 27, 2019 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
